Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer. - de Gruil N; de Groot AF; Wesseling-Rozendaal Y; Keizer D; Koekenbier CS; Vermeer S; Cohen D; Heijns JB; Mandigers CMPW; van de Wouw AJ; Cloos-van Balen M; Ropela JA; et al. (Breast cancer research : BCR, 2026)